TY - JOUR
T1 - Prognostic models for radiation-induced complications after radiotherapy in head and neck cancer patients
AU - Takada, Toshihiko
AU - Damen, Johanna A.A.G.
AU - Tambas, Makbule
AU - Spijker, René
AU - Steenbakkers, Roel J.H.M.
AU - Sharabiani, Marjan
AU - Clementel, Enrico
AU - Langendijk, Johannes A.
AU - Moons, Karel G.M.
AU - Schuit, Ewoud
N1 - Funding Information:
Johannes A Langendijk: received research grants from the Dutch Cancer Society and EU and ravel grants from ESTRO, EHNS, BIR. The department of Radiation Oncology has several research grants with companies that are mainly focusing on improving technological developments in the clinic. The department uses models to guide treatment planning optimization in the so+ware provided or delivered by the companies. Is a board member of the scientific advisory committee of RaySearch and IBA, which also promote using models for treatment optimization. The author will serve as a content expert and will not be involved in data extraction or assessment.
Funding Information:
We would like to thank Vanessa Piechotta (Managing Editor, Cochrane Haematology) and Nina Kreuzberger (Method Editor, Cochrane Haematology) for their assistance regarding the review process.?We thank?Cecilia Schmalbach (Cochrane ENT), Nicole Skoetz (Cochrane Cancer) and Richard Benson (Cambridge University Hospitals NHS Trust) for their valuable comments to improve this review protocol. We also would like to thank Ina Monsef (Information Specialist, Cochrane Haematology) for feedback on the search strategy.
Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2021/5/17
Y1 - 2021/5/17
N2 - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objective The review question is “Which prognostic models are available to predict the risk of radiation-induced side effects after radiation exposure to patients with head and neck cancer, what is their quality, and what is their predictive performance?”. Investigation of sources of heterogeneity between studies We will assess sources of heterogeneity among the prognostic models developed in the eligible studies. The potential sources are study population (e.g. site/stage of cancer, the use of other treatment [surgery and chemotherapy]), predictors, definition and incidence of the predicted outcomes, and prediction horizons. If there are multiple validation studies for the same model, the same sources of between-study heterogeneity will be investigated.
AB - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objective The review question is “Which prognostic models are available to predict the risk of radiation-induced side effects after radiation exposure to patients with head and neck cancer, what is their quality, and what is their predictive performance?”. Investigation of sources of heterogeneity between studies We will assess sources of heterogeneity among the prognostic models developed in the eligible studies. The potential sources are study population (e.g. site/stage of cancer, the use of other treatment [surgery and chemotherapy]), predictors, definition and incidence of the predicted outcomes, and prediction horizons. If there are multiple validation studies for the same model, the same sources of between-study heterogeneity will be investigated.
U2 - 10.1002/14651858.CD014745
DO - 10.1002/14651858.CD014745
M3 - Article
AN - SCOPUS:85105991223
SN - 1465-1858
VL - 2021
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 5
M1 - CD014745
ER -